Envoi Pen Injector Offering access to a pen that aligns with cutting-edge devices available today, at an appealing price point, while reducing the cost, time and risk associated with a custom development: Designed for 3.0 ml and 1.5 ml cartridges An easy-to-scale platform, currently available for 3 ml cartridges Designed for patients managing diabetes, growth hormones, fertility and osteoporosis Benefits of the Envoi Pen Injector Combining a compact design with the capability of administering up to 80 IU in a single injection (~152 mm length) Featuring a limited elongation (~33 mm) for maximum dosing Supporting ease of administration for individuals with small hands or dexterity issues Incorporating a flexible design to accommodate fixed and variable dosing requirements Targeting relatively low dosing force* Handling final assembly for design validation testing (DVT) and production of clinical batches Backed by Our Proven Experience in High-Volume / High-Quality Manufacturing Established Global Footprint Across Three Continents Device Specifications A User-Friendly Patient Experience Supporting Your Product Journey, Every Step of the Way Our comprehensive technical documentation package helps support your U.S
According to the Mounjaro FDA prescribing information, injection-site reactions redness, itching, swelling, or pain at the injection point occurred in approximately 3-7% of participants across the SURPASS clinical trials depending on dose
doi: 10.1186/s12957-024-03553-9
Our mission centers on delivering accessible, affordable, and top-notch healthcare solutions to individuals and communities spanning multiple states
SUSTAIN-6 Trial (Semaglutide) Semaglutide was shown to lower the risk of heart attack and stroke by 26% in high-risk patients
In addition, GLP-1R is moderately in the lung, heart, kidney, blood vessels, pancreatic alpha cells, and peripheral nervous system, with no expression of GLP-1R in liver, skeletal muscle or adipose tissue (109112)
